# VIOLETTE (ceralasertib): what clinicians are saying

> 24 statements from 7 sources (6 posts, 1 paper), 4 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).
- NCT ID: NCT03330847
- Registry: https://clinicaltrials.gov/study/NCT03330847
- Sponsor: AstraZeneca
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: ceralasertib plus olaparib; adavosertib plus olaparib
- Indication: metastatic triple-negative breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: 4737b1b26a08a1ca4647be9c3ade0740e7ade96387c7b158048bbdd6fc24ae17

## Counts

- Commentary sources screened: 19
- Sources cited by verified statements: 7
- Verified statements: 24
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 4
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 6
- Speakers cited: 6
- Cited speakers with a verified identity: 5
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 2
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 2
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist expresses disappointment with VIOLETTE, relaying no significant progression-free survival gain with ceralasertib–olaparib. An organization sees possible activity beyond HRR mutations but considers the clinical significance limited. Another medical oncologist links adavosertib–olaparib’s discontinuation to toxicity. A speaker suggests functional HRD or replication-stress biomarkers might refine selection; their predictive value is not established. These views establish neither routine-care preferences nor broader clinical agreement.

## Question clinicians left open

In VIOLETTE’s second-/third-line, PARP inhibitor-naïve metastatic TNBC setting, what do clinicians need to see in PFS versus olaparib alone to consider response activity with ceralasertib plus olaparib clinically relevant, particularly in non-HRR-mutated disease?

From finding F1 (12 statements from 2 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. VIOLETTE responses: a speaker highlights no significant PFS gain across strata
  - 12 statements from 2 speakers in 5 sources.
  - 1 of the 2 named speakers in this finding holds this view.
  - 1 of the report's 2 cited clinicians.
- F2. Adavosertib–olaparib: a clinician highlights toxicity behind the arm’s closure
  - 7 statements from 2 speakers in 5 sources.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 1 of the report's 2 cited clinicians.
- F3. Non-HRR-mutated TNBC: a speaker asks if biomarkers could predict ATR–PARP benefit
  - 6 statements from 3 speakers in 4 sources.
  - 1 of the 3 named speakers in this finding holds this view.
  - 1 of the report's 2 cited clinicians.
- F4. VIOLETTE in 2017: a speaker looks forward to starting the trial
  - 2 statements from 2 speakers in 2 sources.
  - 1 of the 2 named speakers in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 12 | 9 | 5 | 2 | 3 |
| F2 | 7 | 6 | 5 | 2 | 2 |
| F3 | 6 | 8 | 4 | 3 | 2 |
| F4 | 2 | 2 | 2 | 2 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 1 | 0 | 0 | 7 | 14 | 0 | 4 posts and articles, 1 publication |
| F2 | 1 | 0 | 0 | 0 | 6 | 7 | 1 | 4 posts and articles, 1 publication |
| F3 | 1 | 1 | 0 | 0 | 4 | 8 | 0 | 3 posts and articles, 1 publication |
| F4 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 2 posts and articles |

### Trial dimensions

- Primary endpoint: Progression-free Survival Per Stratum (BICR): F1 (7 shared claims), F3 (1 shared claims)
- Primary endpoint: Progression-free Survival Per Stratum (Sensitivity Analysis): no finding draws on it directly
- Secondary endpoints: F1 (5 shared claims)
- Population and setting: F1 (7 shared claims), F3 (3 shared claims)
- The comparison: F1 (5 shared claims), F2 (5 shared claims), F3 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (4 shared claims), F3 (1 shared claims)
- Design and conduct: F2 (4 shared claims), F4 (1 shared claims)

## Abbreviations

- BICR: blinded independent central review
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- PARP: poly(ADP-ribose) polymerase
- PFS: progression-free survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 24 | Paid |
| Who said each statement: the cited speakers | 6 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 2 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 7 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 2 of the 6 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

8 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free Survival Per Stratum (BICR) | discussed | 7 | 3 |
| Primary endpoint: Progression-free Survival Per Stratum (Sensitivity Analysis) | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 5 | 2 |
| Population and setting | discussed | 9 | 3 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 10 | 4 |
| Safety and tolerability | discussed | 5 | 4 |
| Design and conduct | discussed | 5 | 5 |
| Questions about biomarker refinement and responder biology | discussed | 4 | 2 |
| Early ATR rationale and trial-launch expectations | discussed | 2 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 18 statements · 75%** | | | |
| X threads | 18 | 6 | 18 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 6 statements · 25%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 6 | 1 | not screened |

- Screened window: 2017-12-07 to 2026-10-23
- Cited window: 2017-12-07 to 2026-10-07
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).
- Registry: NCT03330847 (https://clinicaltrials.gov/study/NCT03330847)
- Study IDs: D5336C00001 · 2017-002361-22
- Sponsor: AstraZeneca
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 273 (actual)
- Start: 2018-03-07 (actual)
- Primary completion: 2020-11-13 (actual)
- Primary endpoint: Progression-free Survival Per Stratum (BICR) (Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months))
- Primary endpoint: Progression-free Survival Per Stratum (Sensitivity Analysis) (Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months))
- Intervention: Olaparib Continuous (28-Day cycle) 300 mg BD. (drug)
- Intervention: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). (drug)
- Intervention: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on planned olaparib combination comparisons and HR-pathway stratification in metastatic triple-negative breast cancer.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 42 sources about other trials or topics are not included; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- Relevant discussions that do not name VIOLETTE or use different spellings may be missing; the sources reviewed for this edition do not represent all public HCP commentary.
- Publication-linked summaries, reposts and credited relays should not be counted as independent HCP evaluations or evidence of consensus.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- ClinicalTrials.gov first posted results for the trial on 22 March 2022.
- Exact regulatory-label information for the three study regimens was not available; this report does not assess labeled indications or dosing.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 24 verified statements · 4 from 2 confirmed clinicians
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/violette-nct03330847/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=violette-nct03330847

## Cite

Erudio Health. VIOLETTE (NCT03330847): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/violette-nct03330847

## Questions

### How much does the VIOLETTE report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the VIOLETTE report cover?

24 statements from 7 sources (6 posts, 1 paper), 4 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the VIOLETTE report?

Its preview, yes: get_report_card({ "slug": "violette-nct03330847" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the VIOLETTE report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/violette-nct03330847.json
- Markdown: https://www.erudio.com/reports/violette-nct03330847.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/violette-nct03330847/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "violette-nct03330847"}`
